How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter.

When did VIVUS's stock split?

VIVUS shares reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of VIVUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC) , Sangamo Therapeutics (SGMO) , Anavex Life Sciences (AVXL) , Novavax (NVAX) , General Electric (GE) , Advanced Micro Devices (AMD) , CymaBay Therapeutics (CBAY) , Amarin (AMRN) , Geron (GERN) and Idera Pharmaceuticals (IDRA) .

NASDAQ:VVUS

VIVUS (VVUS) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Free VVUS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.26
▼
$0.47
52-Week Range: N/A

Volume: 2.03 million shs
Average Volume: 1.44 million shs
Market Capitalization: $7.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get VIVUS alerts:

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

About VIVUS Stock (NASDAQ:VVUS)

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Get your free information kit NOW, before it's too late.

VVUS Stock News Headlines

January 8, 2024 | markets.businessinsider.com

VIVUS Provides Update on Pipeline and Program Milestones

May 25, 2023 | it.tmcnet.com

Metaview announces Answers, the world's first conversational AI for the interview process

April 17, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

October 2, 2022 | marketwatch.com

Why aren’t new drugs that can help you lose weight more widely used? - MarketWatch

October 2, 2022 | morningstar.com

'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - Morningstar

September 23, 2022 | finance.yahoo.com

Erectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo Finance

September 16, 2022 | streetinsider.com

Form DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.com

September 9, 2022 | globenewswire.com

Obesity Management Market Expanding at an Impressive CAGR - GlobeNewswire

April 17, 2024 | Priority Gold (Ad)

Biden to Launch “FedNOW” [Move Your Money Now]

August 26, 2022 | finance.yahoo.com

Global Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo Finance

August 26, 2022 | prnewswire.com

Global Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR Newswire

August 17, 2022 | stockhouse.com

2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - Stockhouse

August 15, 2022 | streetinsider.com

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.com

August 11, 2022 | finance.yahoo.com

Kaléo Announces Executive Appointments and New Government Business Unit - Yahoo Finance

August 5, 2022 | marketscreener.com

Icahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.com

August 2, 2022 | benzinga.com

Global Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - Benzinga

July 31, 2022 | businesswire.com

Global Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business Wire

July 26, 2022 | globenewswire.com

Global Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswire

July 14, 2022 | fortune.com

The best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - Fortune

July 5, 2022 | finance.yahoo.com

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo Finance

July 5, 2022 | streetinsider.com

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.com

June 8, 2022 | benzinga.com

Overweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - Benzinga

May 16, 2022 | stockhouse.com

2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - Stockhouse

May 6, 2022 | fool.com

Icahn Enterprises (IEP) Q1 2022 Earnings Call Transcript - The Motley Fool

May 3, 2022 | gurufocus.com

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GuruFocus.com

May 3, 2022 | globenewswire.com

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GlobeNewswire

April 27, 2022 | gurufocus.com

Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - GuruFocus.com

See More Headlines

Receive VVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/06/2020
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:VVUS
CUSIP: 92855110
CIK: 881524
Web: www.vivus.com
Phone: (650) 934-5200
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,500,000.00
Net Margins: -39.28%
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -12.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.43
Quick Ratio: 0.28

Sales & Book Value

Annual Sales: $69.76 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($6.50) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 17,867,000
Free Float: N/A
Market Cap: $7.33 million
Optionable: Optionable
Beta: -0.84

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

John P. Amos
Chief Executive Officer & Director
Mark K. Oki
Chief Financial & Accounting Officer, Senior VP
Santosh T. Varghese
Chief Medical Officer & Senior Vice President
Ted Broman
Vice President-Chemistry, Manufacturing & Control
Tracy Guo
Vice President-Finance

Key Competitors

View All Competitors

VVUS Stock Analysis - Frequently Asked Questions

How were VIVUS's earnings last quarter?: VIVUS, Inc. (NASDAQ:VVUS) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter.
When did VIVUS's stock split?: VIVUS shares reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of VIVUS own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Novavax (NVAX), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Amarin (AMRN), Geron (GERN) and Idera Pharmaceuticals (IDRA).

This page (NASDAQ:VVUS) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

VIVUS (VVUS) Stock Price, News & Analysis

About VIVUS Stock (NASDAQ:VVUS)

VVUS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VVUS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info